MA71255A - Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 - Google Patents
Composés pour le traitement de l'ataxie spinocérébelleuse de type 3Info
- Publication number
- MA71255A MA71255A MA71255A MA71255A MA71255A MA 71255 A MA71255 A MA 71255A MA 71255 A MA71255 A MA 71255A MA 71255 A MA71255 A MA 71255A MA 71255 A MA71255 A MA 71255A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- treatment
- spinocerebellar ataxia
- ataxia type
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263354339P | 2022-06-22 | 2022-06-22 | |
| PCT/US2023/068717 WO2023250316A1 (fr) | 2022-06-22 | 2023-06-20 | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 |
| EP23827977.2A EP4543444A1 (fr) | 2022-06-22 | 2023-06-20 | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71255A true MA71255A (fr) | 2025-04-30 |
Family
ID=89380638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71255A MA71255A (fr) | 2022-06-22 | 2023-06-20 | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4543444A1 (fr) |
| JP (1) | JP2025521545A (fr) |
| KR (1) | KR20250035623A (fr) |
| CN (1) | CN119997954A (fr) |
| AU (1) | AU2023289366A1 (fr) |
| CA (1) | CA3259536A1 (fr) |
| CL (1) | CL2024003939A1 (fr) |
| CO (1) | CO2024017547A2 (fr) |
| CR (1) | CR20240567A (fr) |
| IL (1) | IL317705A (fr) |
| MA (1) | MA71255A (fr) |
| MX (1) | MX2024015863A (fr) |
| PE (1) | PE20250836A1 (fr) |
| WO (1) | WO2023250316A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021009667A (es) | 2019-02-13 | 2021-12-10 | Ptc Therapeutics Inc | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. |
| US12398140B2 (en) | 2019-02-13 | 2025-08-26 | Ptc Therapeutics, Inc. | Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8436043B2 (en) * | 2008-03-05 | 2013-05-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| MA39987A (fr) * | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| MX2021009667A (es) * | 2019-02-13 | 2021-12-10 | Ptc Therapeutics Inc | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. |
| EP3929185A4 (fr) * | 2019-02-19 | 2023-02-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Composé cyclique condensé contenant de l'azote, son procédé de préparation et son utilisation |
-
2023
- 2023-06-20 WO PCT/US2023/068717 patent/WO2023250316A1/fr not_active Ceased
- 2023-06-20 EP EP23827977.2A patent/EP4543444A1/fr active Pending
- 2023-06-20 CA CA3259536A patent/CA3259536A1/fr active Pending
- 2023-06-20 IL IL317705A patent/IL317705A/en unknown
- 2023-06-20 MA MA71255A patent/MA71255A/fr unknown
- 2023-06-20 JP JP2024575231A patent/JP2025521545A/ja active Pending
- 2023-06-20 CR CR20240567A patent/CR20240567A/es unknown
- 2023-06-20 CN CN202380060030.9A patent/CN119997954A/zh active Pending
- 2023-06-20 PE PE2024003069A patent/PE20250836A1/es unknown
- 2023-06-20 AU AU2023289366A patent/AU2023289366A1/en active Pending
- 2023-06-20 KR KR1020247042593A patent/KR20250035623A/ko active Pending
-
2024
- 2024-12-17 MX MX2024015863A patent/MX2024015863A/es unknown
- 2024-12-19 CL CL2024003939A patent/CL2024003939A1/es unknown
- 2024-12-20 CO CONC2024/0017547A patent/CO2024017547A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250035623A (ko) | 2025-03-12 |
| CL2024003939A1 (es) | 2025-05-02 |
| PE20250836A1 (es) | 2025-03-21 |
| CO2024017547A2 (es) | 2025-03-27 |
| IL317705A (en) | 2025-02-01 |
| CN119997954A (zh) | 2025-05-13 |
| EP4543444A1 (fr) | 2025-04-30 |
| CA3259536A1 (fr) | 2023-12-28 |
| AU2023289366A1 (en) | 2025-01-23 |
| CR20240567A (es) | 2025-03-03 |
| WO2023250316A1 (fr) | 2023-12-28 |
| JP2025521545A (ja) | 2025-07-10 |
| MX2024015863A (es) | 2025-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4288059A4 (fr) | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 | |
| EP4301359A4 (fr) | Composés de liaison covalents pour le traitement d'une maladie | |
| MA71255A (fr) | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 | |
| MA51916A (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
| EP3927705A4 (fr) | Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles neurodégénératifs | |
| EP4288441A4 (fr) | Procédés de traitement de l'ataxie spinocérébelleuse de type 3 | |
| MA55973A (fr) | Composé pour le traitement de la goutte ou de l'hyperuricémie | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| EP3877402A4 (fr) | Traitement combiné pour l'hypertension résistante | |
| EP4192453A4 (fr) | Utilisation de dexpramipexole pour le traitement de l'asthme modéré à sévère | |
| EP4301132A4 (fr) | Inhibiteur de rock2 pour le traitement d'une infection virale | |
| EP4232075A4 (fr) | Composés, compositions et méthodes d'utilisation pour le traitement de spondylodèses | |
| EP3931178A4 (fr) | Composés pour la prévention et le traitement d'un dysfonctionnement cognitif post-opératoire | |
| MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP4208137A4 (fr) | Composés et méthodes de traitement d'une infection virale | |
| EP4121403A4 (fr) | Composés nitro-aminoadamantane pour le traitement d'infections par le bêtacoronavirus | |
| EP4181915A4 (fr) | Compositions pour le traitement de l'obésité | |
| EP4052694A4 (fr) | Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire | |
| EP4288054A4 (fr) | Procédés de traitement de l'ataxie spinocérébelleuse de type 3 | |
| MA56186A (fr) | Composés pour le traitement d'une maladie respiratoire | |
| EP4340881A4 (fr) | Anticorps pour le traitement d'alpha-synucléinopathies | |
| EP4274583A4 (fr) | Procédés et composés destinés au traitement de l'ataxie de friedreich | |
| EP4125839A4 (fr) | Composés précurseurs de cystéamine pour le traitement d'infections à bêtacoronavirus | |
| EP4149469A4 (fr) | Utilisation de composés pour le traitement d'infections virales |